source
stringlengths 2
222
| date
stringlengths 19
19
| url
stringlengths 22
853
⌀ | text
stringlengths 0
10k
⌀ | title
stringlengths 0
701
| context_id
stringlengths 1
9
| document_id
stringclasses 2
values | document_type
stringclasses 2
values |
|---|---|---|---|---|---|---|---|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-19 16:15:00
| null |
VANCOUVER, BRITISH COLUMBIA & SEATTLE--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY PROVIDED A CORPORATE UPDATE ON ITS KEY STRATEGIC PRIORITIES FOR 2022 AND 2023 IN ADDITION TO CONFIRMING ITS UPCOMING CLINICAL DEVELOPMENT MILESTONES FOR ZANIDATAMAB AND ZW49. “UPON ASSUMING MY NEW ROLE EFFECTIVE JANUARY 15TH, WE HAVE MOVED QUICKLY TO REVIEW AND CONFIRM KEY STRATEGIC PRIORITIES FOR THE NEAR TERM AND TO E
|
ZYMEWORKS PROVIDES CORPORATE UPDATE ON KEY STRATEGIC PRIORITIES AND OUTLOOK FOR 2022
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-15 08:30:00
| null |
VANCOUVER, BRITISH COLUMBIA & SEATTLE--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY REPORTED, AS REQUIRED BY THE NEW YORK STOCK EXCHANGE LISTED COMPANY MANUAL RULE 303A.08 (THE “NYSE RULE”), AN EQUITY INDUCEMENT AWARD TO MR. KENNETH GALBRAITH, ZYMEWORKS' NEW CHAIR, PRESIDENT AND CHIEF EXECUTIVE OFFICER. IN ACCORDANCE WITH THE NYSE RULE, ZYMEWORKS APPROVED THE GRANT OF THE FOLLOWING EQUITY AWARD TO MR.
|
ZYMEWORKS REPORTS INDUCEMENT GRANT UNDER NEW YORK STOCK EXCHANGE LISTED COMPANY MANUAL RULE
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-05 16:30:00
| null |
VANCOUVER, BRITISH COLUMBIA & SEATTLE--(BUSINESS WIRE)--ZYMEWORKS NAMES BIOTECHNOLOGY INDUSTRY LEADER KENNETH GALBRAITH AS CHAIR AND CEO TO SUCCEED DR. ALI TEHRANI
|
ZYMEWORKS NAMES BIOTECHNOLOGY INDUSTRY LEADER KENNETH GALBRAITH AS CHAIR AND CEO TO SUCCEED DR. ALI TEHRANI
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-12-09 08:30:00
| null |
VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THAT ITS COLLABORATOR, BEIGENE, LTD., HAS DOSED THE FIRST PATIENT IN SOUTH KOREA IN THE HERIZON‑GEA‑01 TRIAL. AS A RESULT OF THIS DEVELOPMENT MILESTONE, ZYMEWORKS WILL RECEIVE A US$8 MILLION PAYMENT UNDER ITS ZANIDATAMAB COLLABORATION AGREEMENT WITH BEIGENE. ZYMEWORKS AND BEIGENE CONTINUE TO WORK TO EXPEDITE THE OPENING
|
ZYMEWORKS ANNOUNCES EXPANSION OF ZANIDATAMAB PIVOTAL TRIAL IN ASIA IN COLLABORATION WITH BEIGENE AND ASSOCIATED MILESTONE PAYMENT
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-12-08 18:00:00
| null |
VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZANIDATAMAB DATA PRESENTED AT THE SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS) DEMONSTRATE ENCOURAGING ANTITUMOR ACTIVITY
|
ZANIDATAMAB DATA PRESENTED AT THE SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS) DEMONSTRATE ENCOURAGING ANTITUMOR ACTIVITY IN HEAVILY PRETREATED PATIENTS WITH HER2-POSITIVE BREAST CANCER
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-11-19 09:21:00
| null |
VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS ANNOUNCES ABSTRACT FOR ZANIDATAMAB IN LATE-LINE HER2-POSITIVE BREAST CANCER AT THE SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS)
|
ZYMEWORKS ANNOUNCES ABSTRACT FOR ZANIDATAMAB IN LATE-LINE HER2-POSITIVE BREAST CANCER AT THE SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS)
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-11-09 08:30:00
| null |
VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS LAUNCHES GLOBAL PHASE 3 ZANIDATAMAB TRIAL IN FIRST-LINE HER2 POSITIVE GASTROESOPHAGEAL ADENOCARCINOMA (GEA)
|
ZYMEWORKS LAUNCHES GLOBAL PHASE 3 ZANIDATAMAB TRIAL IN FIRST-LINE HER2‑POSITIVE GASTROESOPHAGEAL ADENOCARCINOMA (GEA)
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-16 05:30:00
| null |
VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THAT NEW CLINICAL DATA FOR ZANIDATAMAB, A HER2‑TARGETED BISPECIFIC ANTIBODY, DEMONSTRATE PROMISING RESPONSE RATES AND DURABILITY IN FIRST-LINE HER2-POSITIVE GEA. THESE DATA WERE PRESENTED TODAY BY LEAD STUDY INVESTIGATOR, GEOFFREY KU, M.D., MEDICAL ONCOLOGIST AT MEMORIAL SLOAN KETTERING CANCER CENTER (MSK), AT THE ESMO
|
ZANIDATAMAB PHASE 2 CLINICAL TRIAL DEMONSTRATES PROMISING RESPONSE RATE AND DURABILITY IN FIRST-LINE HER2-POSITIVE GASTROESOPHAGEAL ADENOCARCINOMA (GEA) AT THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) ANNUAL CONGRESS
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-12 18:49:00
| null |
VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--THIS PRESS RELEASE ANNOUNCES THE AVAILABILITY OF AN ABSTRACT THAT ZYMEWORKS IS PRESENTING AT THE UPCOMING ESMO CONGRESS
|
ZYMEWORKS ANNOUNCES ABSTRACT FOR ZANIDATAMAB IN FIRST-LINE HER2-EXPRESSING GASTROESOPHAGEAL CANCERS (GEA) AT THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) ANNUAL CONGRESS
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-08-04 16:15:00
| null |
VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2021. “THE SECOND HALF OF 2021 IS AN EXCITING TIME AT ZYMEWORKS AS WE PREPARE TO PRESENT IMPORTANT DATA READOUTS AT UPCOMING MEDICAL CONFERENCES IN SUPPORT OF THE PLANNED LAUNCH OF OUR PIVOTAL TRIAL FOR ZANIDATAMAB IN FIRST-LINE HER2-POSITIVE GASTRIC CANCER,” SAID A
|
ZYMEWORKS REPORTS 2021 SECOND QUARTER FINANCIAL RESULTS
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-08-03 08:30:00
| null |
VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS ANNOUNCES MILESTONE PAYMENT AS JANSSEN ACHIEVES FIRST PATIENT DOSED FOR ITS BISPECIFIC ANTIBODY UTILIZING ZYMEWORKS' THERAPEUTIC PLATFORMS
|
ZYMEWORKS ANNOUNCES MILESTONE PAYMENT AS JANSSEN ACHIEVES FIRST PATIENT DOSED FOR ITS BISPECIFIC ANTIBODY UTILIZING ZYMEWORKS' AZYMETRIC™ AND EFECT™ THERAPEUTIC PLATFORMS
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-07-28 08:30:00
| null |
VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS ANNOUNCES FIRST PATIENT WITH ADVANCED HER2-POSITIVE BREAST CANCER DOSED WITH ZANIDATAMAB IN COMBINATION WITH TUKYSA® AND CHEMOTHERAPY
|
ZYMEWORKS ANNOUNCES FIRST PATIENT WITH ADVANCED HER2-POSITIVE BREAST CANCER DOSED WITH ZANIDATAMAB IN COMBINATION WITH TUKYSA® (TUCATINIB) AND CHEMOTHERAPY
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-04-19 08:30:00
| null |
VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THAT DIANA HAUSMAN, M.D., WILL BE TRANSITIONING OUT OF HER ROLE AS ZYMEWORKS' CHIEF MEDICAL OFFICER (CMO) AND ASSUMING AN EXECUTIVE ADVISORY ROLE UNTIL NOVEMBER 15TH, 2021. NEIL JOSEPHSON, M.D., WHO CURRENTLY OVERSEES ZYMEWORKS' GLOBAL CLINICAL STUDIES IN HIS ROLE AS SENIOR VICE PRESIDENT, CLINICAL RESEARCH, WILL ASSUME
|
ZYMEWORKS ANNOUNCES SUCCESSION PLAN FOR CHIEF MEDICAL OFFICER
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-04-10 08:30:00
| null |
VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS SHOWCASES PRECLINICAL ASSETS, INCLUDING NEW THERAPEUTIC PLATFORM, PROTECT™, AND ZANIDATAMAB MECHANISMS OF ACTION AT AACR ANNUAL MEETING
|
ZYMEWORKS SHOWCASES PRECLINICAL ASSETS, INCLUDING NEW THERAPEUTIC PLATFORM, PROTECT™, AND ZANIDATAMAB MECHANISMS OF ACTION AT AACR ANNUAL MEETING
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-03-10 17:27:00
| null |
VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THE ACCEPTANCE OF FIVE ABSTRACTS FOR POSTER PRESENTATION AT THE UPCOMING AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2021 TAKING PLACE VIRTUALLY FROM APRIL 10 – 15, 2021. THE POSTER PRESENTATIONS WILL BE AVAILABLE ON SATURDAY, APRIL 10 AT 8:30 AM ET ON THE CONFERENCE WEBSITE AS WELL AS THE ZYMEWORKS W
|
ZYMEWORKS ANNOUNCES FIVE PRESENTATIONS AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2021
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-02-24 16:15:00
| null |
VANCOUVER, CANADA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY REPORTED FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2020 AND PROVIDED A SUMMARY OF RECENT BUSINESS AND CLINICAL HIGHLIGHTS. “THROUGHOUT 2020, WE INITIATED AND ADVANCED SEVERAL CLINICAL TRIALS AND ACHIEVED IMPORTANT REGULATORY MILESTONES FOR ZANIDATAMAB AND ZW49,” SAID ALI TEHRANI, PH.D., ZYMEWORKS' PRESIDENT & CEO. “THIS HAS SET
|
ZYMEWORKS REPORTS 2020 YEAR-END FINANCIAL RESULTS
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-02-09 16:30:00
| null |
VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THAT JAMES PRIOUR, FORMER SENIOR VICE PRESIDENT, COMMERCIAL, HAS BEEN PROMOTED TO CHIEF COMMERCIAL OFFICER AND NAMED TO THE COMPANY'S EXECUTIVE COMMITTEE. THE COMMERCIAL TEAM ALSO RECENTLY EXPANDED ITS LEADERSHIP WITH THE ADDITION OF MANNY DUENAS AS VICE PRESIDENT, GLOBAL VALUE & ACCESS. ZYMEWORKS ALSO ANNOUNCED THA
|
ZYMEWORKS EXPANDS COMMERCIAL TEAM AND CREATES NEW R&D ROLE
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-01-27 17:15:00
| null |
VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, ANNOUNCED TODAY THAT THE COMPANY HAS BEGUN ENROLLING PATIENTS INTO THE EXPANSION COHORT PORTION OF THE ONGOING PHASE 1 CLINICAL TRIAL FOR ZW49, ITS NOVEL HER2-TARGETED ANTIBODY-DRUG CONJUGATE (ADC). SUPPORTING DATA FROM THE PHASE 1 DOSE ESCALATION PORTION WERE HIGHLIGHTED TODAY VIA A WEBCAST AND CONFERENCE CALL AND ARE SUMMARIZED BELOW
|
ZYMEWORKS ADVANCES HER2 BISPECIFIC ANTIBODY-DRUG CONJUGATE, ZW49, INTO EXPANSION COHORT STAGE OF CLINICAL DEVELOPMENT
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-01-15 08:30:00
| null |
VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED NEW AND UPDATED CLINICAL DATA FOR THE HER2‑TARGETED BISPECIFIC ANTIBODY ZANIDATAMAB, IN BOTH HER2-EXPRESSING BILIARY TRACT CANCER (BTC) AND GASTROESOPHAGEAL ADENOCARCINOMA (GEA). THE DATA ARE BEING PRESENTED TODAY AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) GASTROINTESTINAL CANCERS SYMPOSIUM, TAKING PLACE VIRTUA
|
ZANIDATAMAB DATA HIGHLIGHT DURABLE ANTITUMOR ACTIVITY IN HER2‑EXPRESSING BILIARY TRACT AND GASTROESOPHAGEAL CANCERS AT ASCO GASTROINTESTINAL CANCERS SYMPOSIUM
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-01-11 08:00:00
| null |
VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY HIGHLIGHTED ITS KEY ACCOMPLISHMENTS IN 2020 AND UPDATED ITS CORPORATE PRIORITIES. “2020 WAS A LEAP FORWARD FOR OUR LEAD CLINICAL PROGRAM IN TERMS OF A POTENTIAL FIRST APPROVAL AND FUTURE APPROVALS,” SAID ALI TEHRANI, PH.D., PRESIDENT AND CEO AT ZYMEWORKS. “THE LAUNCH OF OUR FIRST PIVOTAL TRIAL AND ACHIEVEMENT OF BREAKTHROUGH THER
|
ZYMEWORKS HIGHLIGHTS 2020 ACHIEVEMENTS AND ANNOUNCES CORPORATE PRIORITIES
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-12-10 08:30:00
| null |
VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THE SELECTION OF THREE ABSTRACTS FOR PRESENTATION AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) GASTROINTESTINAL CANCERS SYMPOSIUM, TAKING PLACE VIRTUALLY ON JANUARY 15 – 17, 2021. THE PRESENTATIONS HIGHLIGHT UPDATED CLINICAL DATA FOR THE HER2‑TARGETED BISPECIFIC ANTIBODY, ZANIDATAMAB, IN HER2‑EXPRESSING GASTROESO
|
ZANIDATAMAB CLINICAL DATA SELECTED FOR ORAL PRESENTATION AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) GASTROINTESTINAL CANCERS SYMPOSIUM
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-11-19 08:30:00
| null |
VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE:ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THAT THE EUROPEAN COMMISSION (EC) HAS GRANTED ORPHAN DRUG DESIGNATION FOR ZANIDATAMAB, THE COMPANY'S INVESTIGATIONAL HER2-TARGETED BISPECIFIC ANTIBODY, IN PATIENTS WITH GASTRIC CANCER. “WE ARE ENCOURAGED BY THE EUROPEAN COMMISSION'S AND EUROPEAN MEDICINES AGENCY'S RECOGNITION OF THE BENEFIT THAT ZANIDATAMAB CAN PROVIDE I
|
ZYMEWORKS RECEIVES ORPHAN DRUG DESIGNATION FROM THE EUROPEAN COMMISSION FOR HER2-TARGETED BISPECIFIC ANTIBODY ZANIDATAMAB IN PATIENTS WITH GASTRIC CANCER
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-11-16 16:15:00
| null |
VANCOUVER, BRITISH COLUMBIA & BURLINGAME, CALIF.--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, AND ALX ONCOLOGY HOLDINGS INC. (NASDAQ: ALXO), A CLINICAL-STAGE IMMUNO-ONCOLOGY COMPANY DEVELOPING THERAPIES THAT BLOCK THE CD47 CHECKPOINT PATHWAY, TODAY ANNOUNCED THEY HAVE ENTERED INTO A CLINICAL COLLABORATION TO EVALUATE THE COMBINATION OF ZYMEWORKS' ZANIDATAMAB (FORMERLY ZW25), A HER2-TARGETED BISPECIFIC ANTIB
|
ZYMEWORKS AND ALX ONCOLOGY ANNOUNCE CLINICAL COLLABORATION EVALUATING ZANIDATAMAB WITH THE CD47 BLOCKER ALX148 IN PATIENTS WITH ADVANCED HER2‑EXPRESSING BREAST CANCER
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-11-03 16:15:00
| null |
VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY REPORTED FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2020. “ZANIDATAMAB'S CLINICAL DEVELOPMENT CONTINUED TO EXPAND THIS QUARTER, HAVING OPENED NEW SITES ACROSS THE GLOBE FOR THE PIVOTAL TRIAL IN HER2-AMPLIFIED BILIARY TRACT CANCERS TOWARD OUR FIRST POTENTIAL BLA SUBMISSION,” SAID ALI TEHRANI, PH.D., ZYMEWORKS' PRESIDENT
|
ZYMEWORKS REPORTS 2020 THIRD QUARTER FINANCIAL RESULTS
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-08-05 18:30:00
| null |
ZYMEWORKS REPORTS 2020 SECOND QUARTER FINANCIAL RESULTS.Q2 REVENUE $12.4 MILLION VERSUS $7.9 MILLION.QTRLY LOSS PER SHARE $0.77.
|
ZYMEWORKS REPORTS QTRLY LOSS PER SHARE $0.77
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-07-08 19:30:00
| null |
ZYMEWORKS - CO & MERCK SIGNED NEW LICENSE AGREEMENT.ZYMEWORKS - AGREEMENT GRANTS MERCK RIGHT TO DEVELOP ADDITIONAL MULTISPECIFIC ANTIBODY THERAPEUTIC CANDIDATES USING CO'S AZYMETRIC & EFECT PLATFORMS.ZYMEWORKS - TO PROVIDE MERCK WORLDWIDE, ROYALTY-BEARING LICENSE TO RESEARCH, COMMERCIALIZE UP TO 3 NEW MULTISPECIFIC ANTIBODIES FOR MERCK'S THERAPEUTIC TARGETS.ZYMEWORKS INC - CO WILL RECEIVE AN UNDISCLOSED UPFRONT PAYMENT.ZYMEWORKS - IF EACH OF 3 PROGRAMS YIELD APPROVED PRODUCT, CO ELIGIBLE TO RECEIVE UP TO US$411 MILLION IN OPTION EXERCISE FEES & MILESTONE PAYMENTS.ZYMEWORKS - IF EACH OF 3 PROGRAMS YIELD APPROVED PRODUCT, CO ELIGIBLE TO RECEIVE UP TO US$480 MILLION IN COMMERCIAL MILESTONE PAYMENTS, ROYALTIES ON SALES.ZYMEWORKS INC - NEW AGREEMENT DOES NOT IMPACT ORIGINAL AGREEMENT BETWEEN CO & MERCK.
|
ZYMEWORKS & MERCK SIGN NEW LICENSE AGREEMENT
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-05-07 19:30:00
| null |
ZYMEWORKS REPORTS 2020 FIRST QUARTER FINANCIAL RESULTS.Q1 REVENUE $8.3 MILLION VERSUS $11.9 MILLION.EXPECTS TO HAVE CASH TO FUND RESEARCH AND DEVELOPMENT PROGRAMS AND OPERATIONS INTO 2022 AND POTENTIALLY BEYOND.QTRLY LOSS PER SHARE $0.64.
|
ZYMEWORKS POSTS QUARTERLY LOSS PER SHARE OF $0.64
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-01-21 20:30:00
| null |
ZYMEWORKS FILES PRELIMINARY PROSPECTUS SUPPLEMENTS FOR OFFERING OF COMMON SHARES AND PRE-FUNDED WARRANTS.
|
ZYMEWORKS FILES PRELIMINARY PROSPECTUS SUPPLEMENTS FOR OFFERING OF COMMON SHARES AND PRE-FUNDED WARRANTS
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-01-12 13:30:00
| null |
ZYMEWORKS ANNOUNCES AGREEMENT WITH PFIZER AND INITIATION OF A NEW PHASE 2 TRIAL EVALUATING ZW25 IN COMBINATION WITH IBRANCE® (PALBOCICLIB).ZYMEWORKS WILL SPONSOR STUDY, AND PFIZER WILL PROVIDE PALBOCICLIB..PLANS TO INITIATE A REGISTRATION-ENABLING PHASE 2 TRIAL IN PREVIOUSLY-TREATED OR RECURRENT HER2-POSITIVE BILIARY TRACT CANCER IN 2020.
|
ZYMEWORKS ANNOUNCES AGREEMENT WITH PFIZER
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-11-21 22:30:00
| null |
ZYMEWORKS INC. ANNOUNCED UPDATED PHASE 1 DATA FOR SINGLE AGENT ZW25 IN HEAVILY PRETREATED PATIENTS WITH HER2-EXPRESSING SOLID TUMORS IN A MINI ORAL PRESENTATION BY DR. DO-YOUN OH, STUDY INVESTIGATOR AND PROFESSOR AT SEOUL NATIONAL UNIVERSITY, AT THE ESMO ASIA 2019 CONGRESS, TAKING PLACE NOVEMBER 22 - 24 IN SINGAPORE. ZYMEWORKS AND ITS COLLABORATOR BEIGENE LTD. PLAN TO ADVANCE ZW25 INTO POTENTIALLY REGISTRATION-ENABLING GLOBAL STUDIES IN HER2-EXPRESSING BILIARY TRACT CANCER (BTC) AND GASTROESOPHAGEAL ADENOCARCINOMA (GEA), BASED ON THESE DURABLE AND CONSISTENT CLINICAL DATA. THE UPDATED SINGLE AGENT RESULTS OF THE ONGOING PHASE 1 TRIAL OF ZW25 IN PATIENTS WITH HER2-EXPRESSING SOLID TUMORS INCLUDE ADDITIONAL SAFETY AND ANTI-TUMOR ACTIVITY DATA FROM THOSE PRESENTED AT THE ESMO 2019 CONGRESS. DATA WERE REPORTED FROM 69 PATIENTS DIAGNOSED WITH HER2-EXPRESSING SOLID TUMORS OTHER THAN BREAST CANCER WHO RECEIVED ZW25 AT THE RECOMMENDED DOSE OF EITHER 10 MG/KG WEEKLY OR 20 MG/KG EVERY OTHER WEEK. OVERALL, PATIENTS RECEIVED A MEDIAN OF THREE PRIOR SYSTEMIC THERAPIES. THOSE WITH BTC, GEA, AND COLORECTAL CANCER (CRC) RECEIVED A MEDIAN OF 4.5, 3, AND 5.5 PRIOR SYSTEMIC THERAPIES, RESPECTIVELY. FORTY-ONE (59%) PATIENTS RECEIVED PRIOR HER2-TARGETED THERAPIES, INCLUDING 93% OF GEA PATIENTS. ELEVEN PATIENTS WERE DIAGNOSED WITH BTC, 28 WITH GEA, 14 WITH CRC, AND 16 WITH OTHER HER2-EXPRESSING CANCERS, INCLUDING ENDOMETRIAL, OVARIAN, PANCREATIC, AND SALIVARY GLAND. FIFTY-SEVEN OF 69 PATIENTS WERE RESPONSE EVALUABLE AT THE TIME OF DATA CUT-OFF. OVERALL, THE DISEASE CONTROL RATE (DCR) WAS 70%, COMPRISING 25 (44%) PARTIAL RESPONSES AND 15 (26%) WITH STABLE DISEASE, AND 18 (32%) PATIENTS EXPERIENCED DISEASE CONTROL FOR GREATER THAN SIX MONTHS. IN THE NINE EVALUABLE BILIARY TRACT CANCER PATIENTS, THE DCR WAS 78%, AND THE OBJECTIVE RESPONSE RATE (ORR) WAS 67%. IN THE 13 CRC AND 23 GEA PATIENTS, ORRS WERE 46% AND 39%, RESPECTIVELY. NOTABLY, CONFIRMED RESPONSES WERE SEEN ACROSS ADDITIONAL TUMOR TYPES, INCLUDING A 100% DECREASE IN TARGET LESIONS IN A PATIENT WITH PANCREATIC CANCER. THE OVERALL MEDIAN PROGRESSION-FREE SURVIVAL WAS 5.5 MONTHS AND IS STILL EVOLVING. AMONG ALL PATIENTS, ZW25 WAS WELL TOLERATED AS AN OUTPATIENT THERAPY. THE MOST COMMON TREATMENT-RELATED ADVERSE EVENTS (TRAE) WERE DIARRHEA (43%), INFUSION-RELATED REACTION (26%), AND NAUSEA (13%). ALL TRAES WERE GRADE 1 OR 2. ZYMEWORKS’ PHASE 1 STUDY HAS THREE PARTS. FROM PART ONE OF THE STUDY (THE DOSE-ESCALATION PHASE), THE RECOMMENDED SINGLE-AGENT DOSE WAS DETERMINED TO BE 20 MG/KG ONCE EVERY TWO WEEKS OR 10 MG/KG WEEKLY. IN THE SECOND PART OF THE STUDY (THE COHORT EXPANSION PHASE), ADDITIONAL PATIENTS ARE BEING ENROLLED TO FURTHER ASSESS ZW25’S SINGLE-AGENT TOLERABILITY AND ANTI-TUMOR ACTIVITY AGAINST A VARIETY OF CANCER TYPES IN DIFFERENT SETTINGS. THE THIRD PART OF THE STUDY (THE COMBINATION PHASE) IS UNDERWAY AND EVALUATING ZW25 IN COMBINATION WITH SELECTED CHEMOTHERAPY AGENTS IN GASTROESOPHAGEAL AND BREAST CANCER PATIENTS WITH HER2 HIGH OR LOWER HER2 EXPRESSION LEVELS.
|
ZYMEWORKS INC. ANNOUNCES UPDATED PHASE 1 DATA FOR SINGLE AGENT ZW25
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-11-17 22:30:00
| null |
ZYMEWORKS INC. ANNOUNCED THE SELECTION OF AN ABSTRACT HIGHLIGHTING UPDATED SINGLE AGENT DATA FROM THE PHASE 1 CLINICAL TRIAL EVALUATING THE HER2-TARGETED BISPECIFIC ANTIBODY, ZW25, IN PATIENTS WITH HER2-EXPRESSING SOLID TUMORS FOR A MINI ORAL PRESENTATION AT THE ESMO ASIA 2019 CONGRESS, TAKING PLACE NOVEMBER 22 - 24 IN SINGAPORE. ABOUT THE PHASE 1 CLINICAL TRIAL: ZYMEWORKS' PHASE 1 STUDY HAS THREE PARTS. FROM PART ONE OF THE STUDY (THE DOSE-ESCALATION PHASE), THE RECOMMENDED SINGLE-AGENT DOSE WAS DETERMINED TO BE 20 MG/KG ONCE EVERY TWO WEEKS OR 10 MG/KG WEEKLY. IN THE SECOND PART OF THE STUDY (THE COHORT EXPANSION PHASE), ADDITIONAL PATIENTS ARE BEING ENROLLED TO FURTHER ASSESS ZW25'S SINGLE-AGENT TOLERABILITY AND ANTI- TUMOR ACTIVITY AGAINST A VARIETY OF CANCER TYPES IN DIFFERENT SETTINGS. THE THIRD PART OF THE STUDY (THE COMBINATION PHASE) IS UNDERWAY AND EVALUATING ZW25 IN COMBINATION WITH SELECTED CHEMOTHERAPY AGENTS IN GASTROESOPHAGEAL AND BREAST CANCER PATIENTS WITH HER2 HIGH OR LOWER HER2 EXPRESSION LEVELS. MORE INFORMATION ABOUT ZW25 CLINICAL TRIALS CAN BE FOUND AT CLINICALTRIALS.GOV.
|
ZYMEWORKS INC. ANNOUNCES SELECTION OF ZW25 ABSTRACT FOR MINI ORAL PRESENTATION AT THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY ASIA (ESMO ASIA) CONGRESS
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-11-05 21:30:00
| null |
ZYMEWORKS INC FILES FOR OFFERING OF UP TO $75.0 MILLION OF COMMON SHARES - SEC FILING.
|
ZYMEWORKS INC FILES FOR OFFERING OF UP TO $75 MLN OF COMMON SHARES
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-11-05 19:30:00
| null |
ZYMEWORKS REPORTS 2019 THIRD QUARTER FINANCIAL RESULTS.Q3 REVENUE $7.9 MILLION VERSUS $2.1 MILLION.QTRLY LOSS PER SHARE $0.70.AS OF SEPTEMBER 30, 2019, ZYMEWORKS HAD $335.1 MILLION IN CASH AND CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS.
|
ZYMEWORKS REPORTS 2019 THIRD QUARTER FINANCIAL RESULTS
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-11-04 22:30:00
| null |
ZYMEWORKS INC. HAS FILED A SHELF REGISTRATION.
|
ZYMEWORKS INC. HAS FILED A SHELF REGISTRATION.
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-10-27 22:30:00
| null |
ZYMEWORKS INC. ANNOUNCED THE FIRST DATA FROM ITS PHASE 1 STUDY EVALUATING NOVEL BISPECIFIC ANTIBODY ZW25 IN COMBINATION WITH CHEMOTHERAPY IN HER2-EXPRESSING GASTROESOPHAGEAL ADENOCARCINOMA (GEA) IN A POSTER PRESENTATION AT THE AACR-NCI-EORTC INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS, TAKING PLACE OCTOBER 26 - 30 IN BOSTON. THE FDA HAS GRANTED FAST TRACK DESIGNATION TO ZW25 FOR FIRST-LINE HER2-POSITIVE GEA IN COMBINATION WITH STANDARD OF CARE CHEMOTHERAPY, AND A PHASE 2 TRIAL EVALUATING COMBINATION TREATMENT IN THIS SETTING IS ACTIVELY ENROLLING PATIENTS (NCT03929666). THE RESULTS FROM PART THREE OF AN ONGOING PHASE 1 STUDY PRESENT THE SAFETY AND EFFICACY OF ZW25, AT THE RECOMMENDED DOSE OF 20 MG/KG EVERY OTHER WEEK, IN COMBINATION WITH PACLITAXEL OR CAPECITABINE AS A TREATMENT FOR 14 PATIENTS WITH HEAVILY PRETREATED HER2-EXPRESSING GEA. PATIENTS RECEIVED A MEDIAN OF 2.5 PRIOR SYSTEMIC THERAPIES, AND 93% HAD PROGRESSED FOLLOWING TRASTUZUMAB TREATMENT. NINE OF 14 PATIENTS WERE RESPONSE-EVALUABLE. OVERALL, THE MAJORITY OF PATIENTS EXPERIENCED A DECREASE IN THEIR TARGET LESIONS WITH A DISEASE CONTROL RATE OF 78%, COMPRISING FIVE (56%) PARTIAL RESPONSES AND TWO (22%) STABLE DISEASE. THESE RESPONSES WERE OBSERVED IN BOTH LOW AND HIGH HER2-EXPRESSING GEA. AT THE TIME OF THE DATA CUT-OFF, FOUR OF THE FIVE PARTIAL RESPONSES HAD BEEN CONFIRMED, AND FIVE (56%) RESPONSE-EVALUABLE PATIENTS WERE STILL ON STUDY. THE OVERALL SAFETY PROFILE OF ZW25 PLUS CHEMOTHERAPY WAS SIMILAR TO THAT SEEN WITH CHEMOTHERAPY ALONE. THE MOST COMMON TREATMENT-RELATED ADVERSE EVENTS (TRAE) OCCURRING IN TWO OR MORE PATIENTS WERE PRIMARILY GRADE 1 OR 2 AND MANAGEABLE WITH SYMPTOMATIC TREATMENT. OF THE TRAE OCCURRING IN TWO OR MORE PATIENTS, GRADE 3 OR HIGHER EVENTS ATTRIBUTED TO ZW25 AND/OR CHEMOTHERAPY WERE FATIGUE AND NEUTROPENIA (2 PATIENTS EACH) AND STOMATITIS, PERIPHERAL NEUROPATHY, AND HYPOKALAEMIA (1 PATIENT EACH). FIVE PATIENTS HAD CHEMOTHERAPY DOSE REDUCTIONS DUE TO TRAES, BUT NO PATIENTS NEEDED ZW25 DOSE REDUCTIONS DUE TO ADVERSE EVENTS. ZYMEWORKS' PHASE 1 STUDY HAS THREE PARTS. FROM PART ONE OF THE STUDY (THE DOSE-ESCALATION PHASE), THE RECOMMENDED SINGLE-AGENT DOSE WAS DETERMINED TO BE 20 MG/KG ONCE EVERY TWO WEEKS OR 10 MG/KG WEEKLY. IN THE SECOND PART OF THE STUDY (THE COHORT EXPANSION PHASE), ADDITIONAL PATIENTS ARE BEING ENROLLED TO FURTHER ASSESS ZW25'S SINGLE-AGENT TOLERABILITY AND ANTI- TUMOR ACTIVITY AGAINST A VARIETY OF CANCER TYPES IN DIFFERENT SETTINGS. THE THIRD PART OF THE STUDY (THE COMBINATION PHASE) IS UNDERWAY AND EVALUATING ZW25 IN COMBINATION WITH SELECTED CHEMOTHERAPY AGENTS IN PATIENTS WITH HER2 HIGH OR LOWER HER2 EXPRESSION LEVELS.
|
ZYMEWORKS INC. ANNOUNCES PHASE 1 DATA FOR ZW25 IN COMBINATION WITH CHEMOTHERAPY IN ADVANCED GASTROESOPHAGEAL ADENOCARCINOMA AT AACR-NCI-EORTC INTERNATIONAL CONFERENCE
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-10-24 22:30:00
| null |
ZYMEWORKS INC. PRESENTS AT PROTEIN & ANTIBODY ENGINEERING SUMMIT 2019, NOV-18-2019 . VENUE: LISBON CONGRESS CENTER, LISBON, PORTUGAL.
|
ZYMEWORKS INC. PRESENTS AT PROTEIN & ANTIBODY ENGINEERING SUMMIT 2019, NOV-18-2019
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-10-16 22:30:00
| null |
ZYMEWORKS INC. PRESENTS AT STIFEL 2019 HEALTHCARE CONFERENCE, NOV-19-2019 08:00 AM. VENUE: LOTTE NEW YORK PALACE HOTEL, NEW YORK, NEW YORK, UNITED STATES.
|
ZYMEWORKS INC. PRESENTS AT STIFEL 2019 HEALTHCARE CONFERENCE, NOV-19-2019 08:00 AM
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-10-15 22:30:00
| null |
ZYMEWORKS INC. ANNOUNCED THE APPOINTMENT OF KATHRYN O’DRISCOLL TO THE EXECUTIVE TEAM AS CHIEF PEOPLE OFFICER (CPO). MS. O'DRISCOLL BRINGS OVER 20 YEARS OF EXPERIENCE AS AN EXECUTIVE-LEVEL HUMAN RESOURCES LEADER ACROSS LARGE GLOBAL ORGANIZATIONS IN THE TECHNOLOGY AND NON-PROFIT SECTORS. IN HER NEW ROLE AS ZYMEWORKS’ CPO, SHE WILL BE RESPONSIBLE FOR GROWING AND DEVELOPING ITS HIGHLY DIVERSE AND SKILLED WORKFORCE.
|
ZYMEWORKS INC. APPOINTS KATHRYN O’DRISCOLL AS CHIEF PEOPLE OFFICER
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-09-27 22:30:00
| null |
ZYMEWORKS INC. ANNOUNCED UPDATED DATA FROM THE ONGOING MULTI-CENTER PHASE 1 CLINICAL TRIAL EVALUATING ZW25 IN PATIENTS WITH HER2-EXPRESSING SOLID TUMORS, INCLUDING BILIARY TRACT CANCER (BTC), COLORECTAL CANCER (CRC), GYNECOLOGICAL CANCERS, AND GASTROESOPHAGEAL ADENOCARCINOMA (GEA), IN A POSTER DISCUSSION PRESENTATION AT THE ESMO 2019 CONGRESS, TAKING PLACE SEPTEMBER 27, 2019 IN BARCELONA, SPAIN. BASED ON THE DATA FROM THE ONGOING PHASE 1 STUDY, ZYMEWORKS HAS INITIATED A BROAD CLINICAL DEVELOPMENT PROGRAM FOR ZW25 IN MULTIPLE HER2-EXPRESSING CANCERS. IN ADDITION TO THE PHASE 2 BTC TRIAL ANNOUNCED ON SEPTEMBER 28, 2019, ZYMEWORKS IS CONTINUING TO EVALUATE ZW25 AS A POTENTIAL TREATMENT FOR PATIENTS WITH OTHER HER2-EXPRESSING CANCERS, INCLUDING CRC AND GYNECOLOGICAL CANCERS. FOR PATIENTS WITH HER2-EXPRESSING GEA, ZW25 IS BEING DEVELOPED AS A FIRST-LINE TREATMENT IN COMBINATION WITH STANDARD OF CARE CHEMOTHERAPY. ZYMEWORKS ALSO PLANS TO INITIATE A PHASE 2 STUDY OF ZW25 IN COMBINATION WITH A CDK4/6 INHIBITOR AND HORMONE THERAPY IN THIRD-LINE HER2-EXPRESSING, HR-POSITIVE BREAST CANCER. FINDINGS FROM THIS ONGOING PHASE 1 STUDY OF ZW25 IN PATIENTS WITH HER2-EXPRESSING SOLID TUMORS WERE LAST PRESENTED AT THE 2018 EORTC-NCI-AACR SYMPOSIUM. THE UPDATED RESULTS WERE PRESENTED ON SEPTEMBER 28, 2019 BY DR. FUNDA MERIC-BERNSTRAM, M.D., CLINICAL INVESTIGATOR AND CHAIR OF THE DEPARTMENT OF INVESTIGATIONAL CANCER THERAPEUTICS AT THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER. DATA WERE REPORTED FROM 58 PATIENTS DIAGNOSED WITH HER2-EXPRESSING SOLID TUMORS OTHER THAN BREAST CANCER WHO RECEIVED ZW25 AT THE RECOMMENDED DOSE OF EITHER 10 MG/KG WEEKLY OR 20 MG/KG EVERY OTHER WEEK. PATIENTS HAD A MEDIAN AGE OF 61 YEARS AND RECEIVED A MEDIAN OF FOUR PRIOR THERAPIES. THIRTY-TWO (55%) PATIENTS RECEIVED PRIOR HER2-TARGETED THERAPIES INCLUDING 87% OF GEA PATIENTS. OF ALL PATIENTS, 23 WERE DIAGNOSED WITH GEA, 13 WITH CRC, NINE WITH BTC, AND 13 WITH OTHER HER2-EXPRESSING CANCERS, INCLUDING ENDOMETRIAL, OVARIAN, PANCREATIC, AND SALIVARY GLAND. AMONG ALL PATIENTS, ZW25 WAS WELL TOLERATED AS AN OUTPATIENT THERAPY. THE MOST COMMON ADVERSE EVENTS WERE DIARRHEA, INFUSION-RELATED REACTION, AND NAUSEA. ALL TREATMENT-RELATED ADVERSE EVENTS OCCURRING IN 10% OR MORE OF PATIENTS WERE GRADE 1 OR 2.
|
ZYMEWORKS INC. ANNOUNCES UPDATED SINGLE AGENT DATA FOR HER2-TARGETED BISPECIFIC ANTIBODY ZW25 AT EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) CONGRESS
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-28 16:05:00
| null |
ANNUAL MEETING RECONVENED AND ADJOURNED WITHOUT CONDUCTING BUSINESS MEETING TO RECONVENE ON JULY 27, 2023 AT 9:00 AM EDT DEVON, PA., JUNE 28, 2023 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE) (THE “COMPANY”), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR ORPHAN NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT THE ADJOURNED 2023 ANNUAL MEETING OF STOCKHOLDERS (“ANNUAL MEETING”) WAS RECONVENED AND THEN ADJOURNED, WITHOUT CONDUCTING ANY BUSINESS, IN ORDER TO PROVIDE STOCKHOLDERS ADDITIONAL TIME TO CONSIDER AND VOTE ON PROPOSAL 2 TO AMEND THE SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF THE COMPANY TO EFFECT A REVERSE STOCK SPLIT OF THE COMPANY'S OUTSTANDING SHARES OF COMMON STOCK BY A RATIO OF ANY WHOLE NUMBER BETWEEN 1-FOR-2 AND 1-FOR-50, AT ANY TIME PRIOR TO NOVEMBER 1, 2023, THE IMPLEMENTATION AND TIMING OF WHICH SHALL BE SUBJECT TO THE DISCRETION OF THE BOARD OF DIRECTORS OF THE COMPANY.
|
ZYNERBA PHARMACEUTICALS ANNOUNCES FURTHER ADJOURNMENT OF ANNUAL MEETING
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-13 16:05:00
| null |
MEETING ADJOURNED WITH RESPECT TO PROPOSAL 2, REVERSE STOCK SPLIT; COMPANY ENCOURAGES ADDITIONAL STOCKHOLDERS OF RECORD TO VOTE BEFORE RECONVENED MEETING ON JUNE 28, 2023
|
ZYNERBA PHARMACEUTICALS ANNOUNCES PARTIAL ADJOURNMENT OF ANNUAL MEETING
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-05-23 07:00:00
| null |
DEVON, PA., MAY 23, 2023 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR ORPHAN NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED AN ORAL PODIUM PRESENTATION AND POSTER PRESENTATIONS AT THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY ANNUAL MEETING (ASCP 2023), BEING HELD MAY 30 – JUNE 2, 2023, IN MIAMI, FLA. COPIES OF THE PRESENTATIONS WILL BE MADE AVAILABLE ON THE ZYNERBA CORPORATE WEBSITE FOLLOWING THE PRESENTATIONS AT HTTP://ZYNERBA.COM/PUBLICATIONS/.
|
ZYNERBA PHARMACEUTICALS ANNOUNCES PODIUM AND POSTER PRESENTATIONS AT THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY ANNUAL MEETING
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-05-15 07:00:00
| null |
ENROLLMENT CONTINUES IN RECONNECT, A CONFIRMATORY PIVOTAL PHASE 3 TRIAL OF ZYGEL™ IN PATIENTS WITH FRAGILE X SYNDROME; TOPLINE RESULTS EXPECTED FIRST-HALF 2024
|
ZYNERBA PHARMACEUTICALS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-04-12 07:30:00
| null |
ZYGEL CONTINUED TO BE WELL-TOLERATED WITH LONG-TERM ADMINISTRATION AND MAINTAINED CLINICALLY MEANINGFUL IMPROVEMENTS IN CHILDREN AND ADOLESCENTS WITH FRAGILE X SYNDROME
|
ZYNERBA PHARMACEUTICALS PRESENTS DATA ON ZYGEL™ AT THE 55TH GATLINBURG CONFERENCE
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-04-05 07:30:00
| null |
DEVON, PA., APRIL 05, 2023 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR ORPHAN NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THE PRESENTATION OF TWO POSTERS AT THE 55TH GATLINBURG CONFERENCE, BEING HELD APRIL 10-13, 2023, IN KANSAS CITY, MO. COPIES OF THE POSTERS WILL BE MADE AVAILABLE ON THE ZYNERBA CORPORATE WEBSITE FOLLOWING THE PRESENTATION AT WWW.ZYNERBA.COM/PUBLICATIONS.
|
ZYNERBA PHARMACEUTICALS ANNOUNCES POSTER PRESENTATIONS AT THE 55TH GATLINBURG CONFERENCE
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-03-28 07:30:00
| null |
ENROLLMENT CONTINUES IN RECONNECT, A CONFIRMATORY PIVOTAL PHASE 3 TRIAL OF ZYGEL™ IN PATIENTS WITH FRAGILE X SYNDROME; TOPLINE RESULTS EXPECTED FIRST-HALF 2024
|
ZYNERBA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-03-13 16:15:00
| null |
DEVON, PA., MARCH 13, 2023 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR ORPHAN NEUROPSYCHIATRIC DISORDERS, TODAY ISSUED A STATEMENT CONFIRMING THAT IT DOES NOT HOLD CASH DEPOSITS OR SECURITIES AT SILICON VALLEY BANK.
|
ZYNERBA PHARMACEUTICALS CONFIRMS NOT HOLDING CASH DEPOSITS OR SECURITIES AT SILICON VALLEY BANK
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-01-11 08:30:00
| null |
COMPREHENSIVE DATA REVIEW SUGGESTS A CENTRAL ROLE FOR THE ENDOCANNABINOID SYSTEM (ECS) IN NEURONAL DEVELOPMENT, COGNITIVE FUNCTION AND IN THE PATHOGENESIS OF FRAGILE X SYNDROME (FXS)
|
ZYNERBA PHARMACEUTICALS ANNOUNCES PUBLICATION IN THE JOURNAL OF NEURODEVELOPMENTAL DISORDERS DESCRIBING THE ROLE OF THE ENDOCANNABINOID SYSTEM AND CANNABIDIOL THERAPY IN FRAGILE X SYNDROME
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-12-21 07:00:00
| null |
RECONNECT INITIAL SCREENING VISITS ARE BEING ADVERSELY IMPACTED BY ENVIRONMENTAL FACTORS, SUCH AS THE “TRIPLEDEMIC” (HIGH RATES OF RSV, INFLUENZA AND COVID-19); TOPLINE RESULTS NOW EXPECTED FIRST HALF OF 2024
|
ZYNERBA PHARMACEUTICALS ANNOUNCES UPDATE ON RECONNECT, THE PIVOTAL PHASE 3 TRIAL OF ZYGEL™ IN FRAGILE X SYNDROME
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-12-05 07:30:00
| null |
ZYGEL™ ACHIEVED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENTS FROM BASELINE IN MULTIPLE EFFICACY ASSESSMENTS AND WAS GENERALLY WELL-TOLERATED THROUGH 38 WEEKS OF TREATMENT
|
ZYNERBA PHARMACEUTICALS ANNOUNCES POSITIVE LONG-TERM DATA FROM PHASE 2 INSPIRE TRIAL IN 22Q11.2 DELETION SYNDROME AT THE ANNUAL MEETING OF THE AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-11-29 07:00:00
| null |
DEVON, PA., NOV. 29, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR ORPHAN NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THE PRESENTATION OF A POSTER AT THE 61ST ANNUAL MEETING OF THE AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY, BEING HELD DECEMBER 4-7, 2022 IN PHOENIX, ARIZ. A COPY OF THE POSTER WILL BE MADE AVAILABLE ON THE ZYNERBA CORPORATE WEBSITE FOLLOWING THE PRESENTATION AT WWW.ZYNERBA.COM/PUBLICATIONS.
|
ZYNERBA PHARMACEUTICALS ANNOUNCES POSTER PRESENTATION AT THE ANNUAL MEETING OF THE AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-11-28 07:30:00
| null |
STUDY FINDS PATIENTS WITH FRAGILE X WHO HAVE A HIGHLY METHYLATED FMR1 GENE THAT WERE TREATED WITH ZYGEL SHOWED A SIGNIFICANT REDUCTION IN BEHAVIORAL SYMPTOMS COMPARED TO THOSE TREATED WITH PLACEBO
|
ZYNERBA PHARMACEUTICALS ANNOUNCES PUBLICATION OF DATA FROM PHASE 3 CONNECT-FX STUDY OF ZYGEL™ IN THE JOURNAL OF NEURODEVELOPMENTAL DISORDERS
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-11-15 07:30:00
| null |
DEVON, PA., NOV. 15, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR ORPHAN NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT THE EUROPEAN COMMISSION (EC) HAS GRANTED ORPHAN DRUG DESIGNATION TO CANNABIDIOL, THE ACTIVE INGREDIENT IN ITS TRANSDERMAL GEL, ZYGEL™, FOR THE TREATMENT OF 22Q11.2 DELETION SYNDROME (22Q).
|
ZYNERBA PHARMACEUTICALS ANNOUNCES EUROPEAN COMMISSION HAS GRANTED ORPHAN DRUG DESIGNATION FOR ZYGEL™ IN 22Q11.2 DELETION SYNDROME
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-11-14 07:30:00
| null |
ENROLLMENT CONTINUES IN RECONNECT, A CONFIRMATORY PIVOTAL PHASE 3 TRIAL OF ZYGEL™ IN PATIENTS WITH FRAGILE X SYNDROME (FXS); TOPLINE RESULTS EXPECTED SECOND-HALF 2023
|
ZYNERBA PHARMACEUTICALS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-11-02 07:30:00
| null |
DEVON, PA., NOV. 02, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR ORPHAN NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT THE U.S. PATENT AND TRADEMARK OFFICE HAS ISSUED PATENT NO. 11,458,109, TITLED “TREATMENT OF 22Q11.2 DELETION SYNDROME WITH CANNABIDIOL,” WHICH INCLUDES CLAIMS DIRECTED TO METHODS OF TREATING ONE OR MORE BEHAVIORAL SYMPTOMS OF 22Q11.2 DELETION SYNDROME WITH CANNABIDIOL.
|
ZYNERBA PHARMACEUTICALS ANNOUNCES ISSUANCE OF NEW U.S. PATENT FOR ZYGEL™ FOR THE TREATMENT OF 22Q11.2 DELETION SYNDROME
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-10 07:00:00
| null |
DEVON, PA., OCT. 10, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR ORPHAN NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THE PRESENTATION OF A POSTER AT THE 2022 NATIONAL ORGANIZATION FOR RARE DISORDERS (NORD) RARE DISEASES AND ORPHAN PRODUCTS BREAKTHROUGH SUMMIT BEING HELD OCTOBER 17-18, 2022 IN WASHINGTON, D.C. A COPY OF THE POSTER WILL BE MADE AVAILABLE ON THE ZYNERBA CORPORATE WEBSITE FOLLOWING THE PRESENTATION AT WWW.ZYNERBA.COM/PUBLICATIONS.
|
ZYNERBA PHARMACEUTICALS ANNOUNCES POSTER PRESENTATION AT THE NATIONAL ORGANIZATION FOR RARE DISORDERS (NORD) RARE DISEASES AND ORPHAN PRODUCTS BREAKTHROUGH SUMMIT
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-06 07:00:00
| null |
DEVON, PA., OCT. 06, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR ORPHAN NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT THE U.S. PATENT AND TRADEMARK OFFICE HAS ISSUED PATENT NO. 11,458,110, TITLED “TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL,” WHICH INCLUDES CLAIMS DIRECTED TO METHODS OF TREATING FRAGILE X SYNDROME WITH CANNABIDIOL.
|
ZYNERBA PHARMACEUTICALS ANNOUNCES ISSUANCE OF NEW U.S. PATENT FOR ZYGEL™
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-09-29 07:00:00
| null |
DEVON, PA., SEPT. 29, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR ORPHAN NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT STEPHEN O'QUINN, PHARM.D., VICE PRESIDENT, MEDICAL AFFAIRS, ZYNERBA PHARMACEUTICALS, WILL PARTICIPATE IN A PANEL DISCUSSION AT THE 2022 CANTOR NEUROLOGY & PSYCHIATRY CONFERENCE BEING HELD OCTOBER 6-7, 2022 IN SAN FRANCISCO, CALIF. IN ADDITION, ZYNERBA MANAGEMENT WILL HOST INVESTOR MEETINGS.
|
ZYNERBA PHARMACEUTICALS TO PARTICIPATE IN THE CANTOR NEUROLOGY & PSYCHIATRY CONFERENCE
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-09-08 09:15:00
| null |
INSPIRE TRIAL IN 22Q ACHIEVED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENTS FROM BASELINE IN MULTIPLE EFFICACY ASSESSMENTS, WITH EXCELLENT TOLERABILITY PROFILE INSPIRE TRIAL IN 22Q ACHIEVED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENTS FROM BASELINE IN MULTIPLE EFFICACY ASSESSMENTS, WITH EXCELLENT TOLERABILITY PROFILE
|
ZYNERBA PHARMACEUTICALS PRESENTS POSITIVE DATA FROM PHASE 2 INSPIRE TRIAL IN 22Q AT THE SOCIETY FOR THE STUDY OF BEHAVIOURAL PHENOTYPES (SSBP) 24TH INTERNATIONAL RESEARCH SYMPOSIUM
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-08-31 07:00:00
| null |
DEVON, PA., AUG. 31, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR ORPHAN NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THE ACCEPTANCE OF AN ORAL PRESENTATION AT THE SOCIETY FOR THE STUDY OF BEHAVIOURAL PHENOTYPES (SSBP) 24TH INTERNATIONAL RESEARCH SYMPOSIUM, WHICH WILL BE HELD IN OSLO, NORWAY, SEPTEMBER 8-10, 2022. A COPY OF THE PRESENTATION SLIDES WILL BE MADE AVAILABLE ON THE ZYNERBA CORPORATE WEBSITE FOLLOWING THE PRESENTATION AT HTTP://ZYNERBA.COM/PUBLICATIONS/. ADDITIONAL MEETING INFORMATION CAN BE FOUND ON THE SSBP WEBSITE AT HTTPS://SSBP.ORG.UK/.
|
ZYNERBA PHARMACEUTICALS ANNOUNCES ORAL PRESENTATION AT THE SOCIETY FOR THE STUDY OF BEHAVIOURAL PHENOTYPES (SSBP) 24TH INTERNATIONAL RESEARCH SYMPOSIUM
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-08-10 07:00:00
| null |
ENROLLMENT CONTINUES IN RECONNECT, A CONFIRMATORY PIVOTAL PHASE 3 TRIAL OF ZYGEL™ IN PATIENTS WITH FRAGILE X SYNDROME (FXS); TOPLINE RESULTS EXPECTED SECOND-HALF 2023
|
ZYNERBA PHARMACEUTICALS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-07-21 07:00:00
| null |
DEVON, PA., JULY 21, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR ORPHAN NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED IT HAS ENTERED INTO AN EQUITY PURCHASE AGREEMENT FOR UP TO $20 MILLION WITH LINCOLN PARK CAPITAL FUND, LLC (LPC), A CHICAGO-BASED INSTITUTIONAL INVESTOR.
|
ZYNERBA PHARMACEUTICALS ENTERS INTO EQUITY PURCHASE AGREEMENT FOR UP TO $20 MILLION WITH LINCOLN PARK CAPITAL
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-07-07 07:00:00
| null |
DEVON, PA., JULY 07, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED TWO POSTER PRESENTATIONS AT THE 18TH NFXF INTERNATIONAL FRAGILE X CONFERENCE, BEING HELD JULY 14-17, 2022, IN SAN DIEGO, CALIF. IN ADDITION, ZYNERBA MANAGEMENT WILL PRESENT A COMPANY PRESENTATION DURING THE CONFERENCE'S KEYNOTE – INDUSTRY UPDATES SESSION. COPIES OF THE PRESENTATION AND POSTERS WILL BE MADE AVAILABLE ON THE ZYNERBA CORPORATE WEBSITE FOLLOWING THE PRESENTATIONS AT WWW.ZYNERBA.COM/PUBLICATIONS.
|
ZYNERBA PHARMACEUTICALS ANNOUNCES PANEL PRESENTATION AND POSTER PRESENTATIONS AT THE NFXF INTERNATIONAL FRAGILE X CONFERENCE
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-21 20:05:00
| null |
– THE INSPIRE TRIAL ACHIEVED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENTS FROM BASELINE IN MULTIPLE EFFICACY ASSESSMENTS –
|
ZYNERBA PHARMACEUTICALS ANNOUNCES POSITIVE TOP LINE RESULTS FROM OPEN-LABEL PHASE 2 INSPIRE TRIAL OF ZYGEL™ IN 22Q11.2 DELETION SYNDROME
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-01 07:00:00
| null |
– POSTER PRESENTATION HIGHLIGHTS DESIGN ENHANCEMENTS INCORPORATED INTO PIVOTAL RECONNECT TRIAL –
|
ZYNERBA PHARMACEUTICALS PRESENTS DATA ON ZYGEL™ AT THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY ANNUAL MEETING
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-16 07:00:00
| null |
– ENROLLMENT CONTINUES IN RECONNECT, A CONFIRMATORY PIVOTAL PHASE 3 TRIAL OF ZYGEL™ IN PATIENTS WITH FRAGILE X SYNDROME (FXS); TOPLINE RESULTS EXPECTED SECOND-HALF 2023 –
|
ZYNERBA PHARMACEUTICALS REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-11 13:30:00
| null |
– DATA SUPPORT THE LONG-TERM SAFETY AND EFFECTIVENESS OF ZYGEL –
|
ZYNERBA PHARMACEUTICALS PRESENTS LONG-TERM SAFETY AND EFFICACY DATA OF ZYGEL™ IN CHILDREN AND ADOLESCENTS WITH FRAGILE X SYNDROME (FXS) AT THE INTERNATIONAL SOCIETY FOR AUTISM RESEARCH ANNUAL MEETING
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-09 16:57:00
| null |
DEVON, PA., MAY 09, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED AN ORAL PODIUM PRESENTATION AT THE INTERNATIONAL SOCIETY FOR AUTISM RESEARCH ANNUAL MEETING (INSAR 2022), BEING HELD BOTH IN-PERSON AND VIRTUALLY MAY 11-14, 2022, FROM AUSTIN, TX. A COPY OF THE PRESENTATION WILL BE MADE AVAILABLE ON THE ZYNERBA CORPORATE WEBSITE FOLLOWING THE PRESENTATION AT HTTP://ZYNERBA.COM/PUBLICATIONS/.
|
ZYNERBA PHARMACEUTICALS ANNOUNCES PODIUM PRESENTATION AT THE INTERNATIONAL SOCIETY FOR AUTISM RESEARCH ANNUAL MEETING
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-02 07:00:00
| null |
DEVON, PA., MAY 02, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, PRESENTED A POSTER AT THE 2022 SOCIETY OF BIOLOGICAL PSYCHIATRY (SOBP) ANNUAL MEETING, HELD APRIL 28-30, 2022, IN NEW ORLEANS, LA., AND VIRTUALLY. A COPY OF THE POSTER IS AVAILABLE ON THE ZYNERBA CORPORATE WEBSITE AT HTTP://ZYNERBA.COM/PUBLICATIONS/.
|
ZYNERBA PHARMACEUTICALS PRESENTS LONG-TERM SAFETY AND EFFICACY DATA OF ZYGEL™ IN CHILDREN AND ADOLESCENTS WITH FRAGILE X SYNDROME (FXS) AT THE 2022 SOCIETY OF BIOLOGICAL PSYCHIATRY ANNUAL MEETING
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-04-21 07:00:00
| null |
DEVON, PA., APRIL 21, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THE PRESENTATION OF A POSTER AT THE 2022 SOCIETY OF BIOLOGICAL PSYCHIATRY (SOBP) ANNUAL MEETING, BEING HELD APRIL 28-30, 2022, IN NEW ORLEANS, LA., AND VIRTUALLY. A COPY OF THE POSTER WILL BE MADE AVAILABLE ON THE ZYNERBA CORPORATE WEBSITE FOLLOWING THE PRESENTATION AT HTTP://ZYNERBA.COM/PUBLICATIONS/.
|
ZYNERBA PHARMACEUTICALS ANNOUNCES PRESENTATION OF POSTER AT THE 2022 SOCIETY OF BIOLOGICAL PSYCHIATRY ANNUAL MEETING
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-03-22 07:00:00
| null |
DEVON, PA., MARCH 22, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT STEPHEN O'QUINN, VICE PRESIDENT, MEDICAL AFFAIRS, ZYNERBA PHARMACEUTICALS, WILL PARTICIPATE IN A PANEL DISCUSSION AT THE 2022 CANTOR RARE ORPHAN DISEASE SUMMIT TAKING PLACE VIRTUALLY MARCH 29-30, 2022.
|
ZYNERBA PHARMACEUTICALS TO PARTICIPATE IN THE CANTOR RARE ORPHAN DISEASE SUMMIT
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-03-01 06:00:00
| null |
– EUROPEAN COMMISSION GRANTED ORPHAN DRUG DESIGNATION FOR ZYGEL™ IN FRAGILE X SYNDROME (FXS) –
|
ZYNERBA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-02-28 07:00:00
| null |
TOPLINE DATA FROM PHASE 2 INSPIRE TRIAL EXPECTED MID-YEAR 2022 TOPLINE DATA FROM PHASE 2 INSPIRE TRIAL EXPECTED MID-YEAR 2022
|
ZYNERBA PHARMACEUTICALS ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 2 TRIAL OF ZYGEL™ IN 22Q11.2 DELETION SYNDROME
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-02-15 07:00:00
| null |
DEVON, PA., FEB. 15, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THE APPOINTMENT OF ALBERT P. PARKER, AN ACCOMPLISHED INDUSTRY EXECUTIVE WITH OVER 25 YEARS OF PHARMACEUTICAL, BIOTECH AND HEALTHCARE EXPERIENCE, AS CHIEF LEGAL OFFICER AND CORPORATE SECRETARY. HE WILL ASSUME THE DUTIES OF SUZANNE HANLON WHO WILL RETIRE FROM HER POSITION AT THE END OF FEBRUARY 2022.
|
ZYNERBA PHARMACEUTICALS ANNOUNCES PLANNED RETIREMENT OF SUZANNE HANLON AND APPOINTS ALBERT P. PARKER AS CHIEF LEGAL OFFICER
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-04 16:05:00
| null |
– COMPANY PLANS TO FOCUS DEVELOPMENT OF ZYGEL™ IN FXS, ASD AND 22Q –
|
ZYNERBA PHARMACEUTICALS ANNOUNCES CLINICAL DEVELOPMENT UPDATES FOR FXS, ASD, 22Q AND DEE
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-12-06 07:00:00
| null |
DEVON, PA., DEC. 06, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED PRESENTATION DETAILS FOR THE BRAIN FOUNDATION SYNCHRONY 2021 SYMPOSIUM, BEING HELD VIRTUALLY DECEMBER 11-12, 2021. THE PRESENTATION CAN BE ACCESSED BY REGISTERING FOR FREE AT HTTPS://SYNCHRONYSYMPOSIUM.COM/. A COPY OF THE PRESENTATION SLIDES WILL BE MADE AVAILABLE ON THE ZYNERBA CORPORATE WEBSITE FOLLOWING THE PRESENTATION AT HTTP://ZYNERBA.COM/PUBLICATIONS/.
|
ZYNERBA PHARMACEUTICALS ANNOUNCES PRESENTATION AT THE BRAIN FOUNDATION SYNCHRONY 2021 SYMPOSIUM
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-11-22 07:00:00
| null |
DEVON, PA., NOV. 22, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT THE EUROPEAN PATENT OFFICE HAS ISSUED PATENT NO. 3687513, TITLED “TREATMENT OF FRAGILE X SYNDROME AND AUTISM WITH CANNABIDIOL,” WHICH INCLUDES CLAIMS DIRECTED TO METHODS OF TREATING ONE OR MORE BEHAVIORAL SYMPTOMS OF FRAGILE X SYNDROME AND METHODS OF TREATING ONE OR MORE BEHAVIORAL SYMPTOMS OF AUTISM SPECTRUM DISORDER BY TRANSDERMALLY ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF CANNABIDIOL (CBD).
|
ZYNERBA PHARMACEUTICALS ANNOUNCES ISSUANCE OF NEW PATENT IN EU FOR ZYGEL™
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-10-21 07:00:00
| null |
DEVON, PA., OCT. 21, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED ORAL AND POSTER PRESENTATIONS AT THE SOCIETY FOR DEVELOPMENTAL & BEHAVIORAL PEDIATRICS ANNUAL MEETING, BEING HELD VIRTUALLY OCTOBER 21-25, 2021, AND THE 68TH AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY ANNUAL MEETING, BEING HELD VIRTUALLY OCTOBER 18-30, 2021.
|
ZYNERBA PHARMACEUTICALS ANNOUNCES PRESENTATIONS AT TWO UPCOMING SCIENTIFIC CONFERENCES IN OCTOBER
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-10-19 16:15:00
| null |
DEVON, PA., OCT. 19, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THE PRESENTATION OF A POSTER AT THE 2021 NATIONAL ORGANIZATION FOR RARE DISORDERS (NORD) RARE DISEASES AND ORPHAN PRODUCTS BREAKTHROUGH SUMMIT BEING HELD VIRTUALLY OCTOBER 18-19, 2021.
|
ZYNERBA PHARMACEUTICALS ANNOUNCES PRESENTATION OF POSTER AT THE NATIONAL ORGANIZATION FOR RARE DISORDERS (NORD) RARE DISEASES AND ORPHAN PRODUCTS BREAKTHROUGH SUMMIT
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-10-08 07:30:00
| null |
DEVON, PA., OCT. 08, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THE PRESENTATION OF A POSTER AT THE 2021 AMERICAN ACADEMY OF PEDIATRICS (AAP) NATIONAL CONFERENCE & EXHIBITION, WHICH WILL BE HELD VIRTUALLY FROM OCTOBER 8-11, 2021. A COPY OF THE POSTER TITLED, “LONGER TERM TOLERABILITY AND EFFICACY OF ZYN002 CANNABIDIOL TRANSDERMAL GEL IN CHILDREN AND ADOLESCENTS WITH AUTISM SPECTRUM DISORDER (ASD): AN OPEN-LABEL PHASE 2 STUDY (BRIGHT [ZYN2-CL-030]),” WILL BE MADE AVAILABLE ON THE ZYNERBA CORPORATE WEBSITE STARTING TODAY, OCTOBER 8, 2021 AT HTTP://ZYNERBA.COM/PUBLICATIONS/. ADDITIONAL MEETING INFORMATION CAN BE FOUND ON THE AAP WEBSITE AT AAPEXPERIENCE.ORG.
|
ZYNERBA PHARMACEUTICALS ANNOUNCES PRESENTATION OF POSTER AT THE 2021 AMERICAN ACADEMY OF PEDIATRICS NATIONAL CONFERENCE & EXHIBITION
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-20 07:00:00
| null |
DEVON, PA., SEPT. 20, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT ARMANDO ANIDO, CHAIRMAN AND CHIEF EXECUTIVE OFFICER OF ZYNERBA, WILL PARTICIPATE IN A FIRESIDE CHAT DURING THE 2021 CANTOR VIRTUAL GLOBAL HEALTHCARE CONFERENCE ON MONDAY, SEPTEMBER 27, 2021 AT 11:20 A.M. ET.
|
ZYNERBA PHARMACEUTICALS TO PRESENT AT THE CANTOR VIRTUAL GLOBAL HEALTHCARE CONFERENCE
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-09 07:00:00
| null |
DEVON, PA., SEPT. 09, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY PRESENTED DATA FROM THE PHASE 2 BRIGHT TRIAL DESCRIBING TOLERABILITY AND EFFICACY OF ZYGEL (CANNABIDIOL FORMULATED IN A TRANSDERMAL GEL [ZYN002]) IN CHILDREN AND ADOLESCENTS WITH AUTISM SPECTRUM DISORDER (ASD) OVER A LONGER TERM, 38-WEEK TREATMENT PERIOD. THESE DATA WERE PRESENTED AS AN ORAL PRESENTATION AT THE SOCIETY FOR THE STUDY OF BEHAVIOURAL PHENOTYPES (SSBP) CONFERENCE 2021 BEING HELD VIRTUALLY FROM SEPTEMBER 9-10, 2021. A COPY OF THE PRESENTATION IS AVAILABLE ON THE ZYNERBA CORPORATE WEBSITE AT HTTP://ZYNERBA.COM/PUBLICATIONS/.
|
ZYNERBA PHARMACEUTICALS PRESENTS LONGER TERM TOLERABILITY AND EFFICACY DATA OF ZYGEL™ IN CHILDREN AND ADOLESCENTS WITH AUTISM SPECTRUM DISORDER (ASD) AT THE SOCIETY FOR THE STUDY OF BEHAVIOURAL PHENOTYPES (SSBP) CONFERENCE 2021
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-02 07:30:00
| null |
DEVON, PA., SEPT. 02, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT ARMANDO ANIDO, CHAIRMAN AND CHIEF EXECUTIVE OFFICER OF ZYNERBA, WILL PARTICIPATE IN A FIRESIDE CHAT DURING THE H.C. WAINWRIGHT 23RD ANNUAL GLOBAL INVESTMENT CONFERENCE BEING HELD VIRTUALLY SEPTEMBER 13-15, 2021.
|
ZYNERBA PHARMACEUTICALS TO PRESENT AT THE H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-08-09 07:00:00
| null |
DEVON, PA., AUG. 09, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2021, AND PROVIDED AN OVERVIEW OF RECENT OPERATIONAL HIGHLIGHTS AND A PIPELINE UPDATE.
|
ZYNERBA PHARMACEUTICALS REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-08-04 07:30:00
| null |
DEVON, PA., AUG. 04, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT DURING THE CANACCORD GENUITY 41ST ANNUAL GROWTH CONFERENCE BEING HELD VIRTUALLY ON WEDNESDAY, AUGUST 11, 2021 AT 1:30 P.M. ET.
|
ZYNERBA PHARMACEUTICALS TO PRESENT AT THE CANACCORD GENUITY 41ST ANNUAL GROWTH CONFERENCE
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-07-07 07:30:00
| null |
DEVON, PA., JULY 07, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT ARMANDO ANIDO, CHAIRMAN AND CHIEF EXECUTIVE OFFICER OF ZYNERBA, WILL PRESENT A COMPANY OVERVIEW DURING THE LADENBURG THALMANN VIRTUAL HEALTHCARE CONFERENCE ON WEDNESDAY, JULY 14, 2021 AT 12:00 P.M. ET.
|
ZYNERBA PHARMACEUTICALS TO PRESENT AT THE LADENBURG THALMANN VIRTUAL HEALTHCARE CONFERENCE
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-06-11 12:30:00
| null |
DEVON, PA., JUNE 11, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, PRESENTED A POSTER TODAY AT SLEEP 2021, THE 35TH ANNUAL MEETING OF THE ASSOCIATED PROFESSIONAL SLEEP SOCIETIES, LLC. A COPY OF THE POSTER IS AVAILABLE ON THE ZYNERBA CORPORATE WEBSITE AT HTTP://ZYNERBA.COM/PUBLICATIONS/.
|
ZYNERBA PHARMACEUTICALS PRESENTS SLEEP DATA FROM STUDY OF ZYGEL™ IN CHILDREN AND ADOLESCENTS WITH BOTH DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHIES (DEE) AND AUTISM SPECTRUM DISORDER (ASD) AT THE ASSOCIATED PROFESSIONAL SLEEP SOCIETIES SLEEP 2021 ANNUAL MEETING
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-06-09 16:05:00
| null |
– 46.4% OF SHARES VOTED, QUORUM NOT ESTABLISHED TO HOLD ANNUAL MEETING –
|
ZYNERBA PHARMACEUTICALS ANNOUNCES ADJOURNMENT OF ANNUAL MEETING
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-06-04 07:30:00
| null |
DEVON, PA., JUNE 04, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THE ACCEPTANCE AND PRESENTATION DETAILS OF A POSTER AT SLEEP 2021, THE 35TH ANNUAL MEETING OF THE ASSOCIATED PROFESSIONAL SLEEP SOCIETIES, LLC, WHICH WILL BE HELD VIRTUALLY FROM JUNE 10-13, 2021. A COPY OF THE POSTER WILL BE MADE AVAILABLE ON THE ZYNERBA CORPORATE WEBSITE AT THE TIME OF PRESENTATION AT HTTP://ZYNERBA.COM/PUBLICATIONS/. ADDITIONAL MEETING INFORMATION CAN BE FOUND ON THE SLEEP WEBSITE AT HTTPS://WWW.SLEEPMEETING.ORG/.
|
ZYNERBA PHARMACEUTICALS ANNOUNCES ACCEPTANCE OF POSTER AT THE ASSOCIATED PROFESSIONAL SLEEP SOCIETIES SLEEP 2021 ANNUAL MEETING
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-06-03 10:00:00
| null |
DEVON, PA., JUNE 03, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, IS PRESENTING A POSTER TODAY FROM 10:00 A.M. – 11:00 A.M. ET IN POSTER SESSION II AT THE 2021 AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY (ASCP) ANNUAL MEETING. A COPY OF THE POSTER IS AVAILABLE ON THE ZYNERBA CORPORATE WEBSITE AT HTTP://ZYNERBA.COM/PUBLICATIONS/.
|
ZYNERBA PHARMACEUTICALS ANNOUNCES PRESENTATION OF EFFICACY AND SAFETY FINDINGS IN CHILDREN AND ADOLESCENTS WITH AUTISM SPECTRUM DISORDER (ASD) AND RELATED DISORDERS AT THE 2021 AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY (ASCP) ANNUAL MEETING
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-05-27 07:30:00
| null |
DEVON, PA., MAY 27, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THE ACCEPTANCE AND PRESENTATION DETAILS OF A POSTER AT THE 2021 AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY (ASCP) ANNUAL MEETING. THE ASCP ANNUAL MEETING IS BEING HELD VIRTUALLY JUNE 1-4, 2021. A COPY OF THE POSTER WILL BE MADE AVAILABLE ON THE ZYNERBA CORPORATE WEBSITE AT THE TIME OF PRESENTATION AT HTTP://ZYNERBA.COM/PUBLICATIONS/.
|
ZYNERBA PHARMACEUTICALS ANNOUNCES ACCEPTANCE OF POSTER AT THE 2021 AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY (ASCP) ANNUAL MEETING
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-05-26 07:30:00
| null |
DEVON, PA., MAY 26, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT ARMANDO ANIDO, CHAIRMAN AND CHIEF EXECUTIVE OFFICER OF ZYNERBA, WILL PRESENT A COMPANY OVERVIEW DURING THE JEFFERIES VIRTUAL HEALTHCARE CONFERENCE ON THURSDAY, JUNE 3, 2021 AT 4:30 P.M. ET.
|
ZYNERBA PHARMACEUTICALS TO PRESENT AT THE JEFFERIES VIRTUAL HEALTHCARE CONFERENCE
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-04-29 14:00:00
| null |
DEVON, PA., APRIL 29, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, IS PRESENTING TWO POSTERS AT THE SOCIETY OF BIOLOGICAL PSYCHIATRY (SOBP) 2021 VIRTUAL MEETING. BOTH POSTERS WILL BE MADE AVAILABLE ON THE ZYNERBA CORPORATE WEBSITE AT THE TIME OF THEIR PRESENTATIONS AT HTTP://ZYNERBA.COM/PUBLICATIONS/.
|
ZYNERBA PHARMACEUTICALS PRESENTS TWO POSTERS AT THE SOCIETY OF BIOLOGICAL PSYCHIATRY 2021 VIRTUAL MEETING
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-04-15 07:30:00
| null |
DEVON, PA., APRIL 15, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THE ACCEPTANCE AND PRESENTATION DETAILS OF TWO POSTERS AT THE SOCIETY OF BIOLOGICAL PSYCHIATRY (SOBP) 2021 VIRTUAL MEETING. THE SOBP ANNUAL MEETING IS BEING HELD VIRTUALLY FROM APRIL 29 THROUGH MAY 1, 2021. A COPY OF THE POSTERS WILL BE MADE AVAILABLE ON THE ZYNERBA CORPORATE WEBSITE AT THE TIME OF PRESENTATIONS AT HTTP://ZYNERBA.COM/PUBLICATIONS/.
|
ZYNERBA PHARMACEUTICALS ANNOUNCES THE ACCEPTANCE OF TWO POSTERS AT THE SOCIETY OF BIOLOGICAL PSYCHIATRY 2021 VIRTUAL MEETING
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-04-06 07:30:00
| null |
DEVON, PA., APRIL 06, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT ARMANDO ANIDO, CHIEF EXECUTIVE OFFICER OF ZYNERBA, WILL PRESENT A COMPANY OVERVIEW DURING THE 20TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE ON MONDAY, APRIL 12, 2021 AT 1:30 P.M. ET.
|
ZYNERBA PHARMACEUTICALS TO PRESENT AT THE NEEDHAM VIRTUAL HEALTHCARE CONFERENCE
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-03-28 08:15:00
| null |
SAN DIEGO, MARCH 28, 2021 /PRNEWSWIRE/ -- JOHNSON FISTEL, LLP IS INVESTIGATING POTENTIAL CLAIMS ON BEHALF OF ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE) ("ZYNERBA " OR THE "COMPANY") AGAINST CERTAIN OF ITS OFFICERS AND DIRECTORS. SPECIFICALLY, A CLASS-ACTION LAWSUIT PENDING IN THE EASTERN DISTRICT OF PENNSYLVANIA AGAINST ZYNERBA AND CERTAIN OF ITS CURRENT AND FORMER OFFICERS RECENTLY SURVIVED DEFENDANTS' ATTEMPTS TO DISMISS THE CASE.
|
ZYNERBA (ZYNE) ALERT: SHAREHOLDER CLASS ACTION SURVIVES MOTION TO DISMISS; SHOULD MANAGEMENT BE HELD ACCOUNTABLE FOR INVESTORS LOSSES? CONTACT JOHNSON FISTEL
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-03-10 06:45:00
| null |
DEVON, PA., MARCH 10, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2020, AND PROVIDED AN OVERVIEW OF RECENT OPERATIONAL HIGHLIGHTS AND A PIPELINE UPDATE.
|
ZYNERBA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-03-04 08:00:00
| null |
DEVON, PA., MARCH 04, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PARTICIPATE IN THE 33RD ANNUAL ROTH CONFERENCE, WHICH WILL BE HELD VIRTUALLY ON MARCH 15-17, 2021.
|
ZYNERBA PHARMACEUTICALS TO PARTICIPATE IN THE 33RD ANNUAL ROTH CONFERENCE
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-12-17 06:30:00
| null |
- SINGLE TRIAL TO BE CONDUCTED IN PATIENTS WITH FRAGILE X SYNDROME TO CONFIRM POSITIVE RESULTS SEEN IN THE POPULATION OF RESPONDERS IN THE CONNECT-FX TRIAL -
|
ZYNERBA PHARMACEUTICALS PROVIDES REGULATORY UPDATE ON ZYGEL™ IN FRAGILE X SYNDROME
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-12-09 15:49:00
| null |
DENVER--(BUSINESS WIRE)--SHUMAN, GLENN & STECKER INVESTIGATES ZYNERBA PHARMACEUTICALS, INC. (ZYNE)
|
SHUMAN, GLENN & STECKER INVESTIGATES ZYNERBA PHARMACEUTICALS, INC.
|
ZYNE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.